Saving 23andMe: Crisis of Confidence

23andMe is considering splitting up its business into two entities—one focused on DNA-testing and the other on drug development—after the stock slid by as much as 10% after second quarter 2024 earnings. The proposed strategic shift arrives at a pivotal moment for 23andMe , a company that once boasted a market cap exceeding $6 billion and now trades for pennies as it faces a Nasdaq delisting.

The problem runs deeper than just missing quarterly forecasts. The split is being seen as a last-ditch attempt to regain stability in a market that has quickly soured on its business model. The rapid decline in share price highlights the volatile nature of the tech and biotech sectors as well as the critical need for agility in strategic planning. All told, there’s been a significant loss of trust in the company's leadership team triggering a massive crisis of confidence.

When 23andMe was founded in 2006, it was met with considerable scepticism. (The FDA even ordered it stop sales of its health testing kits.) Undeterred by setbacks, the company ultimately secured the distinction of being the only FDA-approved product in its category. 23andMe not only pioneered the DNA testing industry but leveraged its scale to venture into the vast (and expensive) realm of genetics-based drug discovery only to run in to significant hurdles.

Its current predicament raises critical questions about the company's choices, including its $400 million acquisition of telehealth company Lemonaid in 2021 several months after it went public. The move, particularly in light of Lemonaid's underwhelming performance and a substantial write-off for 23andMe, spotlights the challenges of integrating acquisitions and pivoting business models.

In addition, external factors such as macroeconomic headwinds, price adjustments, and not least, an October security breach affecting 6.9 million customers, have further compounded the company's challenges. The silence on the breach's impact on DNA-test sales, coupled with a continued decline in this segment points to a pressing need for strategic operational recalibration.

Amid these challenges, 23andMe 's leadership, spearheaded by CEO Anne Wojcicki, faces the daunting task of restoring investor confidence and steering the company towards a promising future. The proposed separation of its business units is perhaps a testament to the belief that specialization and focused strategy could unlock value otherwise overshadowed by the company’s struggles.

23andMe’s dramatic reversal of fortune opens broader concerns for the biotech and health tech industries where innovation, consumer trust, and regulatory compliance form the cornerstone of success. As companies like 23andMe navigate these turbulent waters, they not only shape their destiny but also set precedents for how emerging technologies are integrated into society and how personal data is safeguarded in an era of increasing digital vulnerability.

As the company charts its course forward, investors, analysts, and industry watchers are keenly waiting and watching as they consider the long-term viability and strategic direction of 23andMe in generating results and returns to shareholders. The company's ability to turn around its fortunes could offer valuable lessons in resilience in the face of adversity.

It happened once before for the company back in its early days; it could happen again.

---